Interleukin-17A Antagonist [EPC]

37285 reported adverse events

Drugs of this class: IXEKIZUMAB SECUKINUMAB

These side effects are most commonly reported by patients taking drugs of the Interleukin-17A Antagonist [EPC] class:

# Side effect Count
0 INJECTION SITE PAIN 3931
1 PSORIASIS 3296
2 DRUG INEFFECTIVE 3287
3 INJECTION SITE ERYTHEMA 2214
4 INJECTION SITE REACTION 1798
5 INJECTION SITE SWELLING 1659
6 INCORRECT DOSE ADMINISTERED 1199
7 PRODUCT DOSE OMISSION ISSUE 962
8 PAIN 950
9 COVID-19 923
See all common reactions for Interleukin-17A Antagonist [EPC]

Drugs of the Interleukin-17A Antagonist [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 GRANULOMA SKIN 35 0.0426
1 DACTYLITIS 35 0.0356
2 ENTHESOPATHY 55 0.0351
3 INJECTION SITE URTICARIA 676 0.0275
4 BLOOD PARATHYROID HORMONE DECREASED 39 0.0263
5 INJECTION SITE REACTION 1798 0.0261
6 PSORIASIS 3296 0.0252
7 INJECTION SITE HYPERSENSITIVITY 77 0.0246
8 INJECTION SITE WARMTH 501 0.0243
9 INJECTION SITE CELLULITIS 44 0.0237
See all enriched reactions for Interleukin-17A Antagonist [EPC]